My Best Biotech Stock for 2021
It's only been a couple of years since BridgeBio Pharma (NASDAQ: BBIO) made its stock market debut, and the company already has two new drug applications under review by the Food and Drug Administration. This biotech start-up foundry hasn't had any trouble attracting institutional capital, but most everyday investors have never heard of BridgeBio Pharma or its growing web of wholly owned subsidiaries.
Many of the reasons to buy BridgeBio could also apply to other biotech stocks, but it's the company's unique approach to the unusual business of developing new drugs that makes it my top pick this year. Here's why this under-the-radar biotech has a better chance to beat the market than any of its peers.
Image source: Getty Images.
Source Fool.com
